Scholar Rock Holding Appoints New Leadership Amid Regulatory Progress for SMA Treatment

Scholar Rock Strengthens Leadership Amid Regulatory Milestones

Scholar Rock Holding, a late-stage biopharmaceutical company dedicated to innovative treatments for spinal muscular atrophy (SMA) and other serious diseases, appoints Lisa Wyman as Chief Technical and Quality Officer (CTQO). This strategic hire comes at a pivotal time as the company gears up for its first anticipated drug approval and commercial launch in 2025. With over two decades of experience in technical and quality operations, Wyman's appointment reflects Scholar Rock's commitment to enhancing its operational capabilities. She previously served as Chief Technical Operations Officer at Generate:Biomedicines, where she played a key role in establishing a global technical operations organization. Her expertise in Chemistry, Manufacturing, and Controls (CMC), technical development, and quality operations positions her to significantly contribute to Scholar Rock's mission.

In conjunction with this leadership change, Scholar Rock eliminates the Chief Operating Officer position and is actively searching for a new Chief Financial Officer. Current COO and CFO Ted Myles will transition to a Senior Advisor role in mid-March, marking the end of his tenure in executive leadership. President and CEO Jay Backstrom expresses enthusiasm for Wyman’s appointment, highlighting her leadership as essential for advancing the company’s mission to develop therapies that improve patient lives. The organizational restructuring demonstrates Scholar Rock's focus on refining its operational framework as it prepares for the commercialization of its first product.

Scholar Rock's recent submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab further underscores its commitment to innovation in the SMA landscape. The application, supported by positive results from the Phase 3 SAPPHIRE trial, indicates a statistically significant improvement in motor function for patients already on SMN-targeted treatments. Scholar Rock also plans to file a Marketing Authorization Application with the European Medicines Agency in early 2025.

The company anticipates the FDA's review under its Division of Neurology Products and has requested Priority Review to potentially expedite the process. Apitegromab, a fully human monoclonal antibody that inhibits myostatin activation, is positioned as the first muscle-targeted treatment candidate to demonstrate meaningful motor function improvement in SMA patients. Scholar Rock aims to initiate a Phase 2 OPAL trial for younger SMA patients in mid-2025, furthering its commitment to advancing treatment options in this critical area.

In summary, Scholar Rock's recent leadership changes and regulatory advances signal its determination to solidify its position in the biopharmaceutical sector. With a focus on operational excellence and innovative therapies, the company is poised for significant growth as it approaches key milestones in its clinical pipeline.